Sanofi boosts Lantus insulin production in Ireland
PARIS Feb 13 (Reuters) - French drugmaker Sanofi said on Wednesday it would invest 44 million euros ($59 million) on its site in Waterford, Ireland, to boost production of its top-selling insulin, Lantus.
The company, which has been reshuffling research and production sites in the United States and Europe after the patent loss of several key medicines, aims to start making Lantus at the site in 2016, Sanofi said in a statement.
Lantus is expected to continue its double-digit sales growth after the U.S. Food and Drug Administration this week refused to approve Novo Nordisk's rival insulin Tresiba until the Danish company conducts extra tests for potential heart risks.
- White House reverses, says Obama met uncle and lived with him during law school
- South Africa mourns Mandela, will bury him on December 15 |
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image
- Flights delayed as air pollution hits record in Shanghai
- Microsoft leads disruption of largest infected global PC network